|
Post by compound26 on Dec 4, 2015 15:02:12 GMT -5
|
|
|
Post by compound26 on Dec 8, 2015 0:02:21 GMT -5
Latest comment from tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313Finally found a doctor in New York to prescribe Afrezza for 18 year old daughter. She loves it. Her blood sugar was 312 after eating out in a restaurant. 4 unit dose of Afrezza brought her to 180 in half an hour 130 in an hour. Problem is OXFORD LIBERTY is denying her on the grounds that she would need to have significant visual impairment or other severe complication to be approved. They do not care if Afrezza can prevent complications. Has anyone successfully appealed denial of Afrezza and, if so, on what grounds. She has had about four instances of 20s and 30s on her meter in the past month while away at college, despite the fact we were running her blood sugar high. We want and need an insulin that is out of her system in an hour or an hour and a half. Judging by her results from the sample packets this insulin is fast, effective and A LOT SAFER.
|
|
|
Post by peppy on Dec 8, 2015 0:57:21 GMT -5
Latest comment from tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313Finally found a doctor in New York to prescribe Afrezza for 18 year old daughter. She loves it. Her blood sugar was 312 after eating out in a restaurant. 4 unit dose of Afrezza brought her to 180 in half an hour 130 in an hour. Problem is OXFORD LIBERTY is denying her on the grounds that she would need to have significant visual impairment or other severe complication to be approved. They do not care if Afrezza can prevent complications. Has anyone successfully appealed denial of Afrezza and, if so, on what grounds. She has had about four instances of 20s and 30s on her meter in the past month while away at college, despite the fact we were running her blood sugar high. We want and need an insulin that is out of her system in an hour or an hour and a half. Judging by her results from the sample packets this insulin is fast, effective and A LOT SAFER.This interests me compound. 18 years old her (other) hormones probably in play as well. I do not have experience with insurance. I would use the existing guidelines and the Afrezza FDA information to get approval. In short, I would write a letter saying that Afrezza was indicated for risk of hypoglycemia (18 years old, it would be nice for her to get to eat.)
quote:She has had about four instances of 20s and 30s on her meter in the past month while away at college
From afrezza package insert: screencast.com/t/EyqI9HkK products.sanofi.us/afrezza/afrezza.pdf
www.aace.com/files/dm-guidelines-ccp.pdf 4.Q6. How is Hypoglycemia Managed? 4.Q6.1. Definition The classical definition of hypoglycemia in patients with DM is a low blood glucose level accompanied by symptoms of hypoglycemia (e.g., palpitations, hunger; see section 4.Q6.2) that are relieved by the ingestion of glucose (i.e., the Whipple triad) (178 [EL 4; review NE]). However, hypoglycemia may be asymptomatic, and any blood glucose <70 mg/dL is generally considered hypoglycemia (179 [EL 4; NE]). In addition, hypoglycemia symptoms can occur in the normal glucose range in a patient with very high glucose levels that drop quickly. SMBG can be helpful but is not necessarily diagnostic because of glucose meter inaccuracy. Severe hypoglycemia is defined as any low blood glucose event that requires assistance from another person to administer carbohydrates or glucagon or take other corrective action (179 [EL 4; NE]). 4.Q6.2. Symptoms Hypoglycemia manifests as neurogenic and/or neuroglycopenic symptoms that range in severity from mild to life threatening and include anxiety, palpitations, tremor, sweating, hunger, paresthesias, behavioral changes, cognitive dysfunction, seizures, and coma. Certain hypoglycemia- related responses (psychomotor function) are altered in the elderly compared with younger patients. Although severe hypoglycemia generally results in recognizable symptoms, mild-to-moderate hypoglycemia may remain asymptomatic and unreported in patients with T2D or with hypoglycemia unawareness (179 [EL 4; NE]). 4.Q6.3. Etiology In patients with DM, iatrogenic hypoglycemia stems from an imbalance among insulinogenic therapy, food intake, physical activity, organ function (gluconeogenesis), and counterregulation with glucagon and/orepinephrine (hypoglycemia-associated autonomic failure). Hyperinsulinemia, increased alcohol intake, starvation, and organ failure may be aggravating factors (166 [EL 4; NE]; 180 [EL 4; NE]).
More graphs screencast.com/t/ywErgK7D
|
|
|
Post by compound26 on Dec 8, 2015 9:09:17 GMT -5
update from the same member on tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313/3We have mentioned the hypos and can prove them on the download of the meter. We will pay out of pocket, and I know they have a $150 knocked off the script but is that a one time thing only? I also know their discount is in effect only until next year. We are not new at this and have been at this for ten years. We have successfully appealed for Apidra, had continual appeals for sufficient testing strips, appealed for Dexcom successfully twice (now she won't wear it). We have one more appeal after this one. Problem is the endo who prescribed the scripts seems to have a very busy practice. We have switched endos before who have refused to fight for adequate strips. I hope the endo will follow through with us to the end of the appeal process. Her receptionist told us we can't appeal as the insurance is demanding visual impairment as one of their grounds. Naturally the endo cannot lie. Hoping for the best, and it won't end here. We will appeal at a governmental or State Insurance Board, whatever we can think of we will do. Once Sanofi stops the discount this could get very expensive. She seems to be using quite a bit of Afrezza... the dosing is not equivalent. But, no, not going back to Novolog, Humalog or Apidra. Been there. Done that. There is no comparison .
|
|
|
Post by kball on Dec 8, 2015 9:34:55 GMT -5
update from the same member on tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313/3We have mentioned the hypos and can prove them on the download of the meter. We will pay out of pocket, and I know they have a $150 knocked off the script but is that a one time thing only? I also know their discount is in effect only until next year. We are not new at this and have been at this for ten years. We have successfully appealed for Apidra, had continual appeals for sufficient testing strips, appealed for Dexcom successfully twice (now she won't wear it). We have one more appeal after this one. Problem is the endo who prescribed the scripts seems to have a very busy practice. We have switched endos before who have refused to fight for adequate strips. I hope the endo will follow through with us to the end of the appeal process. Her receptionist told us we can't appeal as the insurance is demanding visual impairment as one of their grounds. Naturally the endo cannot lie. Hoping for the best, and it won't end here. We will appeal at a governmental or State Insurance Board, whatever we can think of we will do. Once Sanofi stops the discount this could get very expensive. She seems to be using quite a bit of Afrezza... the dosing is not equivalent. But, no, not going back to Novolog, Humalog or Apidra. Been there. Done that. There is no comparison .Honestly, these roadblocks make me very uneasy (but also would explain stock perfomance obviously). And her case of demanding 'visual impairment' is the first i've heard of that. But you would think the headaches induced by seeking the damn coverage would cause at the least visual impairment. Christ, I have it as an investor
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2015 9:35:46 GMT -5
Latest comment from tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313Finally found a doctor in New York to prescribe Afrezza for 18 year old daughter. She loves it. Her blood sugar was 312 after eating out in a restaurant. 4 unit dose of Afrezza brought her to 180 in half an hour 130 in an hour. Problem is OXFORD LIBERTY is denying her on the grounds that she would need to have significant visual impairment or other severe complication to be approved. They do not care if Afrezza can prevent complications. Has anyone successfully appealed denial of Afrezza and, if so, on what grounds. She has had about four instances of 20s and 30s on her meter in the past month while away at college, despite the fact we were running her blood sugar high. We want and need an insulin that is out of her system in an hour or an hour and a half. Judging by her results from the sample packets this insulin is fast, effective and A LOT SAFER.18 YO? At that young age, good control of her blood glucose levels is essential to minimize the detrimental effects of the common long term health complications associated with people who have diabetes. Diabetic retinopathy being a big one. This am I received my diatribe email newsletter with the following story in it - diatribe.org/silent-complication-closer-look-diabetic-retinopathyIf I were this young woman's father, I would be recording all the BG readings and put together a before Afrezza and after Afrezza chart and send it, along with a firmly worded letter via certified mail the the CEO of the health plan asking the CEO, if this was his/her child, knowing the ramifications of lack of control of blood glucose levels on long term health, why the CEO believes Afrezza should not be a covered product? Just for fun, the parent should also cc the medical director and key media outlets where the insurance company is headquartered. The value Afrezza brings, clinical and economic, dwarf RAAs and oral meds.
|
|
|
Post by mssciguy on Dec 8, 2015 9:39:06 GMT -5
Latest comment from tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313Finally found a doctor in New York to prescribe Afrezza for 18 year old daughter. She loves it. Her blood sugar was 312 after eating out in a restaurant. 4 unit dose of Afrezza brought her to 180 in half an hour 130 in an hour. Problem is OXFORD LIBERTY is denying her on the grounds that she would need to have significant visual impairment or other severe complication to be approved. They do not care if Afrezza can prevent complications. Has anyone successfully appealed denial of Afrezza and, if so, on what grounds. She has had about four instances of 20s and 30s on her meter in the past month while away at college, despite the fact we were running her blood sugar high. We want and need an insulin that is out of her system in an hour or an hour and a half. Judging by her results from the sample packets this insulin is fast, effective and A LOT SAFER.18 YO? At that young age, good control of her blood glucose levels is essential to minimize the detrimental effects of the common long term health complications associated with people who have diabetes. Diabetic retinopathy being a big one. This am I received my diatribe email newsletter with the following story in it - diatribe.org/silent-complication-closer-look-diabetic-retinopathyIf I were this young woman's father, I would be recording all the BG readings and put together a before Afrezza and after Afrezza chart and send it, along with a firmly worded letter via certified mail the the CEO of the health plan asking the CEO, if this was his/her child, knowing the ramifications of lack of control of blood glucose levels on long term health, why the CEO believes Afrezza should not be a covered product? Just for fun, the parent should also cc the medical director and key media outlets where the insurance company is headquartered. The value Afrezza brings, clinical and economic, dwarf RAAs and oral meds. Someone needs to tell Brandicourt that. He is an MD. He should know these things. Hard to believe that he doesn't see value in ramping up faster.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2015 9:41:48 GMT -5
update from the same member on tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313/3We have mentioned the hypos and can prove them on the download of the meter. We will pay out of pocket, and I know they have a $150 knocked off the script but is that a one time thing only? I also know their discount is in effect only until next year. We are not new at this and have been at this for ten years. We have successfully appealed for Apidra, had continual appeals for sufficient testing strips, appealed for Dexcom successfully twice (now she won't wear it). We have one more appeal after this one. Problem is the endo who prescribed the scripts seems to have a very busy practice. We have switched endos before who have refused to fight for adequate strips. I hope the endo will follow through with us to the end of the appeal process. Her receptionist told us we can't appeal as the insurance is demanding visual impairment as one of their grounds. Naturally the endo cannot lie. Hoping for the best, and it won't end here. We will appeal at a governmental or State Insurance Board, whatever we can think of we will do. Once Sanofi stops the discount this could get very expensive. She seems to be using quite a bit of Afrezza... the dosing is not equivalent. But, no, not going back to Novolog, Humalog or Apidra. Been there. Done that. There is no comparison . "She seems to be using quite a bit of Afrezza" - key point and perhaps Sanofi learned more about this in San Diego. Is it the pricing that is off or does the package (i.e. - cartridge quantity need to be adjusted)? Could it be that a lot of those samples are going to patients on Afrezza because they simply use so much more and this early in the game, with the reimbursement challenges, its just easier to give docs extra samples for patients until a permanent solution is implemented? I believe I am at least partially correct with this assumption. How partially, your guess as good as mine.
|
|
|
Post by mssciguy on Dec 8, 2015 9:44:04 GMT -5
update from the same member on tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313/3We have mentioned the hypos and can prove them on the download of the meter. We will pay out of pocket, and I know they have a $150 knocked off the script but is that a one time thing only? I also know their discount is in effect only until next year. We are not new at this and have been at this for ten years. We have successfully appealed for Apidra, had continual appeals for sufficient testing strips, appealed for Dexcom successfully twice (now she won't wear it). We have one more appeal after this one. Problem is the endo who prescribed the scripts seems to have a very busy practice. We have switched endos before who have refused to fight for adequate strips. I hope the endo will follow through with us to the end of the appeal process. Her receptionist told us we can't appeal as the insurance is demanding visual impairment as one of their grounds. Naturally the endo cannot lie. Hoping for the best, and it won't end here. We will appeal at a governmental or State Insurance Board, whatever we can think of we will do. Once Sanofi stops the discount this could get very expensive. She seems to be using quite a bit of Afrezza... the dosing is not equivalent. But, no, not going back to Novolog, Humalog or Apidra. Been there. Done that. There is no comparison . "She seems to be using quite a bit of Afrezza" - key point and perhaps Sanofi learned more about this in San Diego. Is it the pricing that is off or does the package (i.e. - cartridge quantity need to be adjusted)? Could it be that a lot of those samples are going to patients on Afrezza because they simply use so much more and this early in the game, with the reimbursement challenges, its just easier to give docs extra samples for patients until a permanent solution is implemented? I believe I am at least partially correct with this assumption. How partially, your guess as good as mine. For sure, docs are giving away a lot of samples. That's been established. Sam Finta even tweeted about it.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2015 9:56:29 GMT -5
update from the same member on tudiabetes.org: www.tudiabetes.org/forum/t/insurance-company-denied-afrezza/49313/3We have mentioned the hypos and can prove them on the download of the meter. We will pay out of pocket, and I know they have a $150 knocked off the script but is that a one time thing only? I also know their discount is in effect only until next year. We are not new at this and have been at this for ten years. We have successfully appealed for Apidra, had continual appeals for sufficient testing strips, appealed for Dexcom successfully twice (now she won't wear it). We have one more appeal after this one. Problem is the endo who prescribed the scripts seems to have a very busy practice. We have switched endos before who have refused to fight for adequate strips. I hope the endo will follow through with us to the end of the appeal process. Her receptionist told us we can't appeal as the insurance is demanding visual impairment as one of their grounds. Naturally the endo cannot lie. Hoping for the best, and it won't end here. We will appeal at a governmental or State Insurance Board, whatever we can think of we will do. Once Sanofi stops the discount this could get very expensive. She seems to be using quite a bit of Afrezza... the dosing is not equivalent. But, no, not going back to Novolog, Humalog or Apidra. Been there. Done that. There is no comparison .Honestly, these roadblocks make me very uneasy (but also would explain stock perfomance obviously). And her case of demanding 'visual impairment' is the first i've heard of that. But you would think the headaches induced by seeking the damn coverage would cause at the least visual impairment. Christ, I have it as an investor This same process has been playing out with gileads hep treatments that are over 90% effective and eliminating hep but they charge around 100k for a 3 month treatment. Insurance companies are requiring patients to prove their liver is impacted and if its not they won't cover the medication. They would rather wait till the damage is confirmed, they do not want to pay for the cure due to the cost. I remember a few years ago when the gop was focused on death panels arriving from gov't controlled healthcare (their argument against a single payer system). Well, I find it ironic that the gov controlled portion of the healthcare system covers just about everything at a low copay while the private portion of our healthcare system sounds a lot like the death panels the gop said would be created by a single payer gov run system.
|
|
|
Post by mssciguy on Dec 8, 2015 10:02:52 GMT -5
Honestly, these roadblocks make me very uneasy (but also would explain stock perfomance obviously). And her case of demanding 'visual impairment' is the first i've heard of that. But you would think the headaches induced by seeking the damn coverage would cause at the least visual impairment. Christ, I have it as an investor This same process has been playing out with gileads hep treatments that are over 90% effective and eliminating hep but they charge around 100k for a 3 month treatment. Insurance companies are requiring patients to prove their liver is impacted and if its not they won't cover the medication. They would rather wait till the damage is confirmed, they do not want to pay for the cure due to the cost. I remember a few years ago when the gop was focused on death panels arriving from gov't controlled healthcare (their argument against a single payer system). Well, I find it ironic that the gov controlled portion of the healthcare system covers just about everything at a low copay while the private portion of our healthcare system sounds a lot like the death panels the gop said would be created by a single payer gov run system. So true. The insurance industry is a 25+% tax on the healthcare system. Then, those who are uninsured go to the emergency room (or use Obamacare) when they have health issues and all of those costs must get absorbed by the system. This is not capitalism, it is something else. Likewise with the securities industry. Borderline fraud. I've just about had my fill here. It's called "finance" for a reason. If you opened the books of any big pharma (assuming they'd let you get close), I would bet that you'd find a lot of those dividends are financed with borrowed money... yet this company, MNKD, gets scrutinized completely in every way. Very poor investor relations.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 8, 2015 10:20:24 GMT -5
If you go back and listen to the presentation from earlier today you will hear Matt use the words "real world". What is going on in the real world is very important. Patients are loving Afrezza. Practitioners that are using Afrezza are loving it. It is still my opinion that the biggest issue is that the marketing by Sanofi has been weak. In my opinion patients will push the initial sales by requesting Afrezza from their practitioners but as of this time many do not even know that it exists. Later, practitioners will use Afrezza because of the results they see in their practices, much like I have seen in my practice. That is the real world. The real world is costs. A person of wealth gets sick and goes to the mayo clinic. A poor person gets sick and does what? If a cheaper alternative that works "ok" or "well enough" is available, then that's what insurance companies are going to provide access to. Afrezza is priced too high. Insurance companies are becoming bolder and bolder about their practices and freely admitting they don't want to cover expensive medicines due to the cost. I don't think it's a stretch that the insurance carriers have run some basic numbers of today's cost to cover afrezza vs what's currently available in the marketplace and, realizing that if made available on their forumularies millions and millions of diabetics would transition to afrezza but the cost of that transition would bankrupt the carriers at current pricing - it's not unbelievable that this may very well be the primary reason that carriers have squashed afrezza coverage. Until the price comes down and becomes competitive with other treatments, afrezza imho will continue to be sidelined on formularies. Everyone realizes that anyone can go and get afrezza right now, as long as you can get a script written and are willing to pay cash at the pharmacy?! It's all about cost when it comes to this side of the equation. www.bostonglobe.com/business/2014/05/31/costly-new-hepatitis-treatments-curing-patients-but-straining-health-care-system-finances/SmBE9NoUESxjfgphfqvXKL/story.htmlWe've all read that compliance is an issue with diabetics. However, cost is one of the primary reasons why people dont' comply. So, how does afrezza fit into this problem? Right smack in the middle imo: www.managedcaremag.com/archives/2014/12/health-plans-patients-struggle-pay-high-cost-drugsI used to think if people were willing to pay 900 bucks for an iPhone, why not pay for something really important like afrezza? The answer is because people like iPhones and other bling bling and would be willing to kill to get it. Afrezza? Not so much. People expect their health to just "be there" kinda like how people expect clean water out of their taps and clean air when they step outside for a breath of fresh air. But when it comes to their phones, their cars, their houses? oh they'll do whatever it takes to achieve status. Maybe mnkd should make blingy inhalers with gold trim, different colors, neon lighted, and maybe even one that talks to you like siri. Then maybe diabetics would be willing to pay for afrezza. Or maybe mnkd could create an inhaler than can throw a football or catch a baseball, then maybe people would pay attention.
|
|
|
Post by mssciguy on Dec 8, 2015 10:23:48 GMT -5
If you go back and listen to the presentation from earlier today you will hear Matt use the words "real world". What is going on in the real world is very important. Patients are loving Afrezza. Practitioners that are using Afrezza are loving it. It is still my opinion that the biggest issue is that the marketing by Sanofi has been weak. In my opinion patients will push the initial sales by requesting Afrezza from their practitioners but as of this time many do not even know that it exists. Later, practitioners will use Afrezza because of the results they see in their practices, much like I have seen in my practice. That is the real world. The real world is costs. A person of wealth gets sick and goes to the mayo clinic. A poor person gets sick and does what? If a cheaper alternative that works "ok" or "well enough" is available, then that's what insurance companies are going to provide access to. Afrezza is priced too high. Insurance companies are becoming bolder and bolder about their practices and freely admitting they don't want to cover expensive medicines due to the cost. I don't think it's a stretch that the insurance carriers have run some basic numbers of today's cost to cover afrezza vs what's currently available in the marketplace and, realizing that if made available on their forumularies millions and millions of diabetics would transition to afrezza but the cost of that transition would bankrupt the carriers at current pricing - it's not unbelievable that this may very well be the primary reason that carriers have squashed afrezza coverage. Until the price comes down and becomes competitive with other treatments, afrezza imho will continue to be sidelined on formularies. Everyone realizes that anyone can go and get afrezza right now, as long as you can get a script written and are willing to pay cash at the pharmacy?! It's all about cost when it comes to this side of the equation. www.bostonglobe.com/business/2014/05/31/costly-new-hepatitis-treatments-curing-patients-but-straining-health-care-system-finances/SmBE9NoUESxjfgphfqvXKL/story.htmlWe've all read that compliance is an issue with diabetics. However, cost is one of the primary reasons why people dont' comply. So, how does afrezza fit into this problem? Right smack in the middle imo: www.managedcaremag.com/archives/2014/12/health-plans-patients-struggle-pay-high-cost-drugsI used to think if people were willing to pay 900 bucks for an iPhone, why not pay for something really important like afrezza? The answer is because people like iPhones and other bling bling and would be willing to kill to get it. Afrezza? Not so much. People expect their health to just "be there" kinda like how people expect clean water out of their taps and clean air when they step outside for a breath of fresh air. But when it comes to their phones, their cars, their houses? oh they'll do whatever it takes to achieve status. Maybe mnkd should make blingy inhalers with gold trim, different colors, neon lighted, and maybe even one that talks to you like siri. Then maybe diabetics would be willing to pay for afrezza. Or maybe mnkd could create an inhaler than can throw a football or catch a baseball, then maybe people would pay attention. I have felt exactly the same the same way since seeing the first of Havas' goofy ads. All wrong. Needs to be sexy. Need a Lauren Kronen, need a Sam Finta. People like sexy stuff... It's almost like Sanofi was trying to fail. An American company would never had made those blunders.
|
|
|
Post by compound26 on Dec 8, 2015 11:09:51 GMT -5
Real world results with Afrezza
This is a continuation of my girlfriends experience with Afrezza, from approval to script to now her first A1C reading of 7.4. She has been on treatment for two of the last three month and her last A1C reading before afrezza was 7.8. On average her A1C's have been 7.5 for the last several years.
In addition to changing to Afrezza she also switched to toujeo and completely dumped the pump. She absolutely loves not having to use the pump anymore. One common characteristic many have reported when making the switch to toujeo is that it takes 10-14 days for the treatment to really settle into a diabetics system. She was no exception and for about 12 days her numbers were all over the place with a few readings in the 300's and one in the 400's. Once she got through this transition period things settled down immensely and have only been better and better with time.
There is also a transition period with Afrezza that I have not heard many discuss. This information, I believe, is valuable for those just starting this treatment and is worth sharing. There is a learning curve that she went through not only in how to time treatment (this was the easy part) but also in the physical act of inhaling Afrezza. At first she did have a reflexive cough, aided with sips of water before and after inhaling (thanks Sam), which caused her to be timid at first when she inhaled. There were times initially where she would take a reading huff, and nothing would happen. No reduction in blood sugar. She does not use a CGM so it could have been that her BS was actively on the rise, but we think it has more to do with user experience. If you are afraid to inhale or don't insert the inhaler appropriately its possible (we believe) to ineffectively deliver afrezza to the lungs. Fast forward two months and it appears that afrezza is working faster for her and lowering her BS more than ever before.
She has learned HOW to huff and is now effectively delivering Afrezza to her lungs as designed. I have seen a few people report similar results "I huffed and nothing happened". In our opinion this is user error which can be corrected with time and experience.
As of today her blood sugar control just seems to get better and better. She has learned how to inhale, how to time her doses, toujeo is completely onboard, and it appears that A1c readings in the 6's are in her future. Her BS log she has used since starting afrezza calculates a reading of 6.9 but I have noticed many users report actual A1C's higher than the calculated A1C. Taken at absolute value an improvement of 0.4 since her last Endo appointment is exciting and encouraging and any improvement is an improvement in her health which in the end is the real goal. As a user she will absolutely refill her script due only to convenience and being able to dump the pump. She has been in meetings all morning and I have not gotten details from her discussion with her Endo this morning but I I will share those once she tells me what he said.
Wish her luck on continued improvement in her treatment and we will keep you posted when her next A1C is taken. Good luck and best health to all diabetics.
|
|
|
Post by irrationalexubera on Dec 8, 2015 11:29:50 GMT -5
And her case of demanding 'visual impairment' is the first i've heard of that. But you would think the headaches induced by seeking the damn coverage would cause at the least visual impairment. Christ, I have it as an investor that's genius, kball, in the saddest way possible. i'd laugh if i wasn't trying to keep down my breakfast right now b/c of today's pps attack. this short cabal is relentless and well-funded and they're gonna get it sub-$1 for a time. holy smokes.
|
|